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Abstract
Background: Listeria monocytogenes is a highly versatile bacterial carrier system for introducing
protein, DNA and RNA into mammalian cells. The delivery of tumor antigens with the help of this
carrier into tumor-bearing animals has been successfully carried out previously and it was recently
reported that L. monocytogenes is able to colonize and replicate within solid tumors after local or
even systemic injection.
Methods:  Here we report on the delivery of two prodrug converting enzymes, purine-
deoxynucleoside phosphorylase (PNP) and a fusion protein consisting of yeast cytosine deaminase
and uracil phosphoribosyl transferase (FCU1) into cancer cells in culture by L. monocytogenes.
Transfer of the prodrug converting enzymes was achieved by bacterium mediated transfer of
eukaryotic expression plasmids or by secretion of the proteins directly into the host cell cytosol
by the infecting bacteria.
Results: The results indicate that conversion of appropriate prodrugs to toxic drugs in the cancer
cells occured after both procedures although L. monocytogenes-mediated bactofection proved to be
more efficient than enzyme secretion 4T1, B16 and COS-1 tumor cells. Exchanging the
constitutively PCMV-promoter with the melanoma specific P4xTETP-promoter resulted in melanoma
cell-specific expression of the prodrug converting enzymes but reduced the efficiencies.
Conclusion: These experiments open the way for bacterium mediated tumor specific activation
of prodrugs in live animals with tumors.
Background
Cancer remains one of the most deadly diseases world-
wide with the number of cases – especially of melanoma
– steadily increasing [1]. Melanoma can be treated by sur-
gical removal at early stages, but once tumor cells have
disseminated the current medical therapies are rather inef-
fective. New approaches for anti-cancer therapy are there-
fore needed. Among the most promising, more recent
developments are the gene directed enzyme prodrug ther-
apies (GDEPT) [2].
Published: 10 April 2008
BMC Cancer 2008, 8:94 doi:10.1186/1471-2407-8-94
Received: 9 January 2008
Accepted: 10 April 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/94
© 2008 Stritzker et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:94 http://www.biomedcentral.com/1471-2407/8/94
Page 2 of 10
(page number not for citation purposes)
All GDEPT operate with the same basic concept: a non-
toxic prodrug is converted into a toxic drug inside of cells
which were transformed with a gene construct encoding
the enzyme needed for the prodrug-drug conversion. For
the complete curing of a tumor, transfer of this gene must
occur either into all tumor cells or a transformed cell does
release enough of the toxic drug to kill the surrounding
non-transformed cells. Such "bystander effect" was
described for a number of prodrug/drug systems, includ-
ing the conversions of 5-Fluorocytosine (5-FC) by cyto-
sine deaminase [3], that of 6-Methylpurine-deoxyriboside
(MePdR) by the purine nucleoside phosphorylase (PNP)
[4-6] or of Fludarabine by the same enzyme [4,5,7,8]. It is
crucial that a prodrug-drug converting enzyme is
expressed in tumors only. Several strategies were devel-
oped to reach this specificity which include the different
tumor inoculation methods (reviewed in [9]), conjugate
antibody systems directed to specific cell surface antigens,
and application of tissue-specific promoters to control the
expression of the prodrug converting enzyme (reviewed in
[10]).
Tumor-specific promoters have been described for several
tumor models especially melanoma [11-16]. One such
promoter was constructed by fusing four copies of a
mouse tyrosinase enhancer element (TE) to the human
tyrosinase promoter (TP). The resulting synthetic pro-
moter P4xTETP was shown to be preferentially expressed in
tyrosinase-expressing melanomas [15].
L. monocytogenes is a facultative intracellular bacterium
that replicates efficiently in the cytosol of a wide range of
mammalian cells [17]. This microorganism was shown to
be an highly versatile carrier for delivering protein anti-
gens, including tumor antigens, directly into the cytosol of
infected cells thereby elicting protective cellular immune
responses against these antigens (for review see [18]). Vir-
ulence-attenuated strains of L. monocytogenes were also
used to deliver eucaryotic expression plasmids into mam-
malian cells [19-23]. Furthermore, it was recently reported
that  L. monocytogenes is able to colonize and replicate
within solid tumors after local [24,25] or even systemic
injection [26].
In this report, we applied L. monocytogenes-mediated pro-
tein- and DNA-delivery strategies to introduce the prod-
rug-drug converting enzymes, purine nucleoside
phosphorylase (PNP) and a fusion protein consisting of
yeast cytosine deaminase and uracil phosphoribosyl
transferase (FCU1) into tumor cells and compared the
efficiency of the tumor cell inhibition by these two
approaches in several tumor cell lines. Furthermore, a
melanoma specific promoter was used to enhance specif-
icity of the DNA-delivery strategy.
Methods
Strains and plasmids
L. monocytogenes ΔaroA/B trpS (WL-150), pTRPS was used
as host strain in which pTRPS was replaced by the plas-
mids described in (Fig. 1). E. coli DH10b was used as host
for all DNA cloning experiments.
DNA-delivery plasmids were derived from pSP118 [22].
For the construction of pSP118-P4xTETP, P4xTETP was PCR
amplified with primers 4xTETP-PstI-for (5'-ctatcgataggtac-
cctgcagagttcctgccag-3') and 4xTETP-NotI-rev (5'-cacaaggcg-
gccgcgaactggctaattggagtcac-3') using pGL3 4xTETP (kindly
provided by S. Hemmi) [15] as template. The 4xTETP-
fragment and pSP118 were ligated after cutting with PstI
and NotI resulting in pSP118-P4xTETP. Egfp was subcloned
from pSP118-PCMV-EGFP [22] into pSP118-P4xTETP by NotI
restriction and subsequent ligation from which pSP118-
P4xTETP-EGFP was obtained. Fcu1 was PCR amplified using
primers FCU1-NotI-Kozak-for (5'-aaaaaagcggccgctcgccac-
catggtgacagggggaatggc-3') and FCU1-NotI-rev (5'-
aaaaaagcggccgcttaaacacagtagtatctgtc-3') with pCIneo-
FCU1 as template [27], thereby introducing NotI-sites and
a Kozak sequence for efficient translation initiation at the
5'-end of the open reading frame. The resulting fragment
was introduced into pSP118 and pSP118-P4xTETP using
NotI restriction resulting in pSP118-PCMV-FCU1 and
pSP118-P4xTETP-FCU1. Plasmids pSP118-PCMV-PNP and
pSP118-P4xTETP-PNP were obtained after PCR amplifica-
tion of a translation initiation signal from pCMVβ (Clon-
tech) using primers TLI-NotI-for (5'-
gtacccgcggccgcaattcccggggatcg-3') and TLI-rev (5'-aatgtgt-
ggggtagccatggtgacttcttttttgct-3') and the open reading
frame of deoD from E. coli chromosomal DNA using prim-
ers deoD-for (5'-agcaaaaaagaagtcaccatggctaccccacacatt-3')
and deoD-NotI-rev (5'-aaaaaagcggccgcttactctttatcgcccagc-
3') followed by recombinant PCR of the two fragments
using TLI-NotI-for and deoD-NotI-rev. The resulting frag-
ment was cloned into pSP118 and pSP118-P4xTETP using
NotI.
For protein delivery deoD was amplified using the primers
deoD-BamHI-for (5'-aaaaaaggatccatggctaccccacacattaat-
3') and deoD-SacISalI-rev (5'-aaaaaacagctggtcgacttactctt-
tatcgcccagcag-3') with E. coli chromosomal DNA as tem-
plate. The resulting framgment was cut with BamHI and
SacI as was pSP2 PCMV [22](thereby removing ply118, trpS
and PCMV) and ligation resulted in pUNK PactA-SP-PNP. The
trpS gene was again introduced as described previously
[22] using the introduced SalI site resulting in the protein
delivery plasmid pSP0-PactA-SP-PNP.
Cell culture and prodrug treatments
COS-1 (Cercopithecus aethiops kidney fibroblasts), 4T1
(murine mammary gland tumor; kindly provided by E.
Lukanidin), and B16 (murine skin melanoma; kindly pro-BMC Cancer 2008, 8:94 http://www.biomedcentral.com/1471-2407/8/94
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vided by J. Becker) cells were cultured in RPMI 1640
medium supplemented with 2 mM L-glutamine (Gibco,
Germany) (RPMI) and 10% fetal calf serum (FCS, Bio-
chrom, Germany), and were maintained at 37°C in a 5%
CO2 atmosphere.
For prodrug treatment, cells were seeded in 24-well plates
4 days prior prodrug addition. Bactofection was carried
out as reported previously [22] and started 3 days before
addition of prodrugs. In brief, cells were washed with
RPMI, infected for 1 h with a multiplicity of infection
(MOI) of 5 bacteria per cell, washed again with RPMI,
incubated with gentamicin-containing medium (100 μg/
ml) for 1 h which was replaced by medium containing 10
μg/ml gentamicin for subsequent culture.
For protein-delivery, cells were infected with MOI 200 five
hours prior to prodrug addition for 1 h. Cells were washed
with RPMI and cultivated with gentamicin-containing
medium (100 μg/ml) which was replaced with medium
containing 10 μg/ml gentamicin after another 1 h. All
cells were trypsinized, diluted, and reseeded in 96 well
plates (approximately 2 × 103 cells per well resuspended
in 100 μl RPMI containing 10% FCS) 1 h before prodrug
addition. Prodrugs were then added in another 100 μl
medium resulting in a final concentration of 50 μM for
MePdR (Gibco, Germany), 88 μM for Fludarabine (kindly
provided by Schering, Germany) and 1 mM for 5-FC
(Sigma, Germany) and the prodrug containing medium
was left on the cells till the end of the experiment.
Cell viability assay
The amount of viable cells after prodrug addition was
measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT, Sigma), following the
manufacturer's instructions. At 3, 5, or 7 days after prod-
rugs were added, medium was replaced by 50 μl MTT
solution (2.5 mg/ml MTT dissolved in RPMI without phe-
nol red) and incubated for 4 h at 37°C in a 5% CO2
atmosphere. After removal of the MTT solution 1 N HCl
diluted in isopropanol was added and the probes were
measured at a wavelength of 570 nm. Non-prodrug
treated cells were used as reference and were considered as
100% viable.
HPLC assay of MePdR
HPLC assay was performed as described earlier [14]. In
brief, 100 μl cell supernatant was boiled for 15 min and
cell debris was removed by centrifuging at 14000 rpm for
15 min at room temperature. Thirty microliters of the
supernatant were injected onto a Waters 625 LC-system
chromatogroph equipped with a Waters 486 tunable
absorbance detector (Waters GmbH, Germany). A Nucle-
osil 120-5 C18 (4 × 250 mm) column (Machery Nagel,
Germany) was used with a mobile phase of 50 mM
NH4H2PO4 and 90% acetonitrile (Roth, Germany) (flow
rate of 1.0 ml/min). MePdR (and MeP) were detected at a
UV wavelength of 254 nm, and were identified and quan-
Construction of the recombinant plasmids used for DNA –  (a) and protein-delivery (b) Figure 1
Construction of the recombinant plasmids used for 
DNA – (a) and protein-delivery (b). Both approaches 
use the same plasmid backbone consisting of an E. coli origin 
of replication (oriE1), repD and repE as genes needed for lis-
terial replication, a erythromycin resistance cassette (ermAM) 
and the gene needed for the balanced lethal system trpS with 
its own promoter (PtrpS). (a) The genes egfp, deoD, and fcu1 
were inserted under the control of the PCMV or P4XTETP pro-
moters and fused to a poly-adenylation signal. The autolysis 
cassette consists of the phage lysin gene ply118 under the 
control of the listerial promoter PactA. (b) The E. coli-derived 
gene deoD is put under the control of PactA and genetically 
fused to the signal sequence (SP) for Sec-dependent secre-
tion of ActA.BMC Cancer 2008, 8:94 http://www.biomedcentral.com/1471-2407/8/94
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tified by comparing their retention times and absorption
spectra with authentic samples.
Flow cytometry analysis
Three days after infection, bactofected cells were
trypsinized and resuspended with PBS. Cell viability was
determined by staining cells with propidium iodide (PI,
1.0 μg/ml). Since nonviable cells tend to fluoresce at a
similar wavelength as EGFP, PI-positive cells were gated
out from the measurement. A minimum of 5 × 104 cells
were then measured using an Epics XL flow cytometer
(Beckman Coulter) and data analysis was performed
using WinMDI 2.8 (J. Trotter 1993–1998). Cells infected
with corresponding strains not encoding EGFP served as
negative control. Cells infected for 4 h with WL-150 pSP0-
PactA-GFP were analyzed with the same method.
Antibody production and Western blot analysis
PNP was overexpressed in E. coli M15 using the pQE30
QIAexpress-system (Qiagen, Germany). Therefore, deoD
was PCR amplified using 6His-BamHI-deoD-for (5'-
gataaaggatccgctaccccacacatt-3') and deoD-HindIII-rev (5'-
caattaaagcttatcgcccagcagaac-3') with E. coli chromosomal
DNA as template and cloned into pQE30 using BamHI
and  HindIII restriction sites. 6His-PNP expression was
induced by addition of 1 mM IPTG and prepared under
native conditions on a Ni-NTA column as described by the
manufacturer. Lysis buffer contained 50 mM NaH2PO4,
300 mM NaCl, and 10 mM imidazole; wash buffer con-
tained 50 mM NaH2PO4, 300 mM NaCl, and 20 mM imi-
dazole; and elution buffer contained 50 mM NaH2PO4,
300 mM NaCl, and 250 mM imidazole.
Fifty microgram purified 6His-PNP were suspended in
Montanide adjuvans (Merck, Germany) and injected
intraperitoneally into CD-1 mice. After 4 weeks, this pro-
cedure was repeated and serum was harvested 10 days
later.
For Western blot analysis 50 ml of exponentially growing
Listeria-cultures were centrifuged and the pellet was resus-
pended in 100 μl/OD600 4× Laemmli buffer. Proteins in
the supernatant were precipitated on ice for one hour with
10% Trichloroacetic acid. Pelleted proteins were washed
with acetone and dissolved in 500 μl 4× Laemmli buffer.
Proteins from mammalian cells were isolated from cells
either bactofected for 3 d or infected with the protein-
delivery strain for 4 h. Isolation was performed from a 10
cm culture dish using 500 μl RIPA lysis buffer (0.15 M
NaCl, 50 mM Tris-HCl, 1% NP-40, 0.5% Deoxycholic
acid, 0.1% SDS) with subsequent removal of DNA using
sepharose. 15 μl of the supernatant were mixed with 15 μl
4× Laemmli buffer.
After incubation of the protein solution at 98°C for 5 min
30 μl were loaded on a 15% SDS-polyacrylamid gel and
electrophoresis was performed by the method of Laemmli
[28]. Immunoblotting was performed by a semidry
method, with Hybond-ECL nitrocellulose membranes
(Amersham Biosciences, Germany). Equal protein load
was confirmed by Ponceau S-staining of the nitrocellulose
membrane. After incubation with horseraddish peroxi-
dase-conjugated secondary antibodies (Dianova, Ger-
many) and a chemiluminescens-based immunoblot assay
(ECL, Amersham Biosciences, Germany) was performed
according to the provided instructions.
Results
Differential expression of P4xTETP in melanoma cells
Different DNA-delivery plasmids were constructed and
introduced into an attenuated L. monocytogenes (Lm)
strain carrying deletions in aroA, aroB [29], and trpS [22]
(WL-150). All DNA-delivery plasmids constructed in this
study were derived from the recently described vectors
pSP118 and pSP0. These plasmids were stabilized by
inserting the trpS gene (essential for cell viability) into the
plasmid and simultaneous deletion of the chromosomal
trpS copy from the genome. The plasmid pSP118 carried
in addition the recently designed autolysis cassette con-
sisting of a phage lysin gene (ply118) under the control of
the listerial actA promoter PactA [21]. The introduced genes
encoding the prodrug/drug converting enzymes used in
this approach were placed under the control of the pro-
moter PCMV or that of the melanoma-specific P4xTETP pro-
moter (Fig. 1a).
For the expression analysis we used COS-1 cells (trans-
formed green African monkey kidney cells) that can be
transformed with the Listeria as DNA carrier at high rates
[22], B16 melanoma cells deriving from a fast growing
murine melanoma, and 4T1 cells deriving from a stage 4
breast cancer. These cancer cell lines were transformed at
different efficiencies by WL-150 pSP118-PCMV-EGFP as
determined by flow cytometry of the EGFP-expressing
cells (Fig. 2). Transformation with WL-150 pSP118-
P4xTETP-EGFP carrying egfp cDNA under the control of the
melanoma-specific P4xTETP promoter led to EGFP-express-
ing B16 melanoma cells at a frequency of 3.6% while
COS-1 cells yielded less than 0.3% and 4T1 cells only
about 0.04% EGFP-expressing cells (Fig. 2), demonstrat-
ing the specificity of the P4xTETP promoter for the B16
melanoma cells in the bactofection approach.
Delivery of prodrug/drug-converting gene constructs to 
tumor cell lines
For this study we used two different genes encoding prod-
rug-drug converting enzymes. Gene fcu1 encodes a fusion
protein of yeast cytosine deaminase and uracil phosphori-
bosyl transferase which is highly active in converting of 5-BMC Cancer 2008, 8:94 http://www.biomedcentral.com/1471-2407/8/94
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Fluorocytosine (5-FC) into the toxic 5-Fluorouracil and
further to 5-Fluoruridine (5-FU) [27]. The gene deoD (E.
coli) encodes a purine-nucleoside phosphorylase (PNP)
which converts the prodrug 6-Methylpurine deoxyribo-
side as well as 9H-Purin-6-amine, 2-fluoro-9-(5-O-
phosphono-β-D-arabinofuranosyl) (Fludarabine) to the
cell toxic compounds 6-Methylpurine (MeP) and 2-Fluor-
oadenine (F-Ade) respectively [4]. The expression of the
prodrug/drug converting gene constructs (PNP (for
MePdR and Fludarabine) and FCU1 (for 5-FC)) were
placed under the control of PCMV or P4xTETP. The efficiency
of prodrug-drug conversion was monitored by elimina-
tion of cells in the three different cancer cell lines (COS-1,
B16 and 4T1) 3 days after DNA delivery. To determine the
cell growth the cells were diluted and reseeded in 96 well
plates prior to addition of the indicated prodrugs which
were added at a final concentration of 50 μM for MePdR,
88 μM for Fludarabine, and 1 mM for 5-FC. The results are
shown in Fig. 3(a–i) as the % of viable cells after prodrug
treatment compared to untreated cells. Cell viability was
measured by the MTT-test.
The data indicate that all three enzymes were functional in
COS-1 cells and lead to rapid cell death (Fig. 3a,d,f) when
WL-150 was used to introduce the expression cassettes
under control of the PCMV promoter. COS-1 cells without
infection or transformed with Lm  strains encoding
enzymes not able to convert the applied prodrug, conse-
quently were not affected by prodrug addition (Fig.
3a,d,f). In contrast, 4T1 cells were inhibited efficiently and
highly specifically by both 5-FC upon infection with WL-
150 pSP118-PCMV-FCU1 and MePdR when infected with
WL-150 pSP118-PCMV-PNP. Fludarabine proved to be
rather toxic for 4T1 cells and a concentration of 88 μM
resulted already in the inhibition of non-infected cells
(Fig. 3e). Unspecific obstruction was also observed when
using lower concentrations (44 and 30 μM). Less than 15
μM Fludarabine allowed complete survival of the cells but
not enough prodrug was converted to the toxic compo-
nent to affect the 4T1 cells upon infection with WL-150
pSP118-PCMV-PNP (data not shown).
In B16 melanoma cells cell-specific expression of PNP and
FCU1 was obtained using the melanoma-specific P4xTETP-
promoter (Fig. 3c,i). However, cell inhibition after treat-
ment of the transformed cells with the prodrugs 5-FC, and
MePdR, respectively, was not as efficient as with the same
drugs after enzyme production using PCMV. Eradication of
the entire cell population was obtained with the PCMV con-
structs only (Fig. 3c,f,i).
Development of Listeria as cytosolic protein secretion 
vector
As alternative to the above described delivery of expres-
sion plasmid transfer for prodrug converting enzyme pro-
duction into cancer cells, we constructed Lm  strains
capable to express and secrete the respective prodrug/drug
converting enzyme directly into the host cell cytosol.
Therefore, we chose PNP, since FCU1 is a yeast protein
and may require posttranslational modification for its
function.
To facilitate PNP secretion from Listeria predominantly in
the cytosol of the Lm-infected cells the deoD gene (encod-
ing PNP) was cloned in frame downstream of the pro-
moter and the secretion signal sequence of the listerial
actA gene. ActA is produced in the cytosol of Lm-infected
mammalian cells where it is responsible for actin polym-
erization needed for intra- and intercellular movement of
L. monocytogenes [30]. The PactA-SP-PNP cassette was
inserted into the recently described Lm lethal balanced
plasmid pSP0 [31] resulting in pSP0-PactA-SP-PNP which
was then introduced into WL-150 (Fig. 1b). Western blot
analysis of protein preparations from the supernatant and
the cell pellet showed that PNP was efficiently secreted by
this Lm strain (Fig. 4a). Supernatants of logarithmically
grown WL-150 pSP0-PactA-SP-PNP and (as control) WL-
150 pSP0 cultured in BHI and supplemented with 1% (w/
v) AmberliteTM XAD-4 to enhance PactA  activity [32]
were incubated with 100 μM MePdR for 6 h and conver-
sion to the toxic MeP was determined by HPLC analysis
(Fig. 4b). The results showed that 85% of MePdR were
Determination of the fraction of (E)GFP-positive viable cells Figure 2
Determination of the fraction of (E)GFP-positive via-
ble cells. The cancer cell lines 4T1, B16 and COS-1 were 
bactofected with WL-150 pSP118-PCMV-EGFP (PCMV) and 
WL-150 pSP118-P4xTETP-EGFP (P4xTETP), respectively, result-
ing in optimal EGFP production by the bactofected cells after 
3 days or these cells were infected with WL-150 pSP0-PactA-
GFP (PactA) resulting in GFP synthesis inside the bacteria 
which was determined 4 h post infection.BMC Cancer 2008, 8:94 http://www.biomedcentral.com/1471-2407/8/94
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converted to MeP by the supernatant of a WL-150 pSP0-
PactA-SP-PNP culture while no conversion was obtained in
the control supernatant. Similar results were obtained
with lysed bacteria indicating that MePdR can not be con-
verted by the L. monocytogenes derived purine deoxyribo-
nucleoside phosphorylases (encoded by deoD and pnp)
annotated in the Lm genome [33] (see also http://geno
list.pasteur.fr/ListiList/).
After infection of 4T1, B16 and COS-1 cells with WL-150
pSP0-PactA-SP-PNP at a MOI of 200 for 5 h the prodrug
treatment was initiated. Prodrug-dependent inhibition of
all cell types was observed when MePdR was added at a
final concentration of 50 μM (Fig. 3a–c) to the cultures.
However, the addition of 88 μM Fludarabine did not
result in specific reduced proliferation of 4T1, B16 or
COS-1 cells infected with this Lm secretion strain.
Listeria mediated DNA delivery to tumor cells results in 
efficient prodrug conversion
In a recent study Critchley et al. 2004 [34] reported pro-
tein-delivery to be more efficient in comparison to DNA-
delivery in prodrug therapy using engineered E. coli vehi-
cles. The authors based their conclusion on the findings
that a higher fraction of GFP expressing cells was found
after protein-delivery than after DNA-delivery.
Our results shown in Fig. 3a–f of this paper suggest, how-
ever, a significantly higher conversion efficiency of the
prodrug by the enzyme after DNA delivery than after the
Inhibition of COS-1- (a, d, g), 4T1- (b, e, h), and B16- (c, f, i) cells bactofected with genes for prodrug-converting enzymes and  treated with the indicated prodrug at different time points as result of comparing prodrug-treated versus non-treated cell sur- vival measured by MTT-assay Figure 3
Inhibition of COS-1- (a, d, g), 4T1- (b, e, h), and B16- (c, f, i) cells bactofected with genes for prodrug-convert-
ing enzymes and treated with the indicated prodrug at different time points as result of comparing prodrug-
treated versus non-treated cell survival measured by MTT-assay. The cells were bactofected with WL-150 pSP118-
PCMV-PNP, WL-150 pSP118-PCMV-FCU1, WL-150 pSP118-P4xTETP-PNP, and WL-150 pSP118-P4xTETP-FCU1, or infected with 
the protein secreting strain WL-150 pSP0-PactA-SP-PNP and subsequently treated with 50 μM MePdR (a, b, c), 88 μM Fludarab-
ine (d, e, f), or 1 mM 5-FC (g, h, i); as control un-infected cells were used.BMC Cancer 2008, 8:94 http://www.biomedcentral.com/1471-2407/8/94
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protein-delivery approach. To determine whether this dif-
ference was due to the use of L. monocytogenes as bacterial
carrier WL150 carrying pSP0-PactA-GFP encoding GFP
under the control of the listerial actA  promoter was
employed as measure of GFP expression inside infected
COS-1 cells using a flow cytometer. The results (Fig. 2)
showed that the majority of the infected cells indeed did
harbour GFP-expressing bacteria similar to the results
obtained with the E. coli as carrier system. But, although
the fraction of cells producing enzymes for prodrug con-
version was higher with the protein-delivery approach,
the amount of PNP produced in the entire cell popula-
tions is higher after DNA delivery (Fig. 5a). Furthermore,
densitometrical scanning of the Western blot revealed a
4–6 lesser PNP expression in B16 cells when deoD was
under the control of P4xTETP promoter in contrast to the
PCMV construct.
In addition, a quantitative comparison of the PNP activity
by the two approaches was performed by measuring the
amount of the generated toxic compound (MeP). Culture
media were taken 7 d after prodrug addition and the non
cleaved MePdR concentration was measured by HPLC-
analysis. The results shown in Fig. 5b confirmed findings
described earlier in Fig. 3 and Fig. 5a.
The reduction of MePdR concentration correlated strictly
with the amount of PNP generation. Strain WL-150
pSP118-PCMV-PNP as vector resulted in close to 100%
conversion of MePdR to MeP in COS-1 and B16 cells, and
80% conversion rate was achieved in 4T1 cells respec-
tively. In contrast, strain WL-150 pSP118-P4xTETP-PNP
yielded about 40% prodrug conversion in B16 melanoma
cells and no conversion was observed in 4T1 or COS-1
cells (Fig. 5b).
PNP sectretion and prodrug conversion activity Figure 4
PNP sectretion and prodrug conversion activity. 
Secretion of PNP by WL-150 pSP0-PactA-SP-PNP (a) The 
amount of secreted PNP was determined by Western blot 
analysis with PNP-specific antibodies using listerial cell lysates 
(CL) or supernatant proteins (SN) obtained by TCA precipi-
tation of cell-free media after growth of WL-150 pSP0 (con-
trol) or WL-150 pSP0-PactA-SP-PNP (Pnp). (b) Prodrug-drug 
conversion activity of secreted PNP determined by incuba-
tion of 100 μM MePdR with the cell-free supernatants from 
cultures of logarithmically grown WL-150 pSP0 or WL-150 
pSP0-PactA-SP-PNP at 37°C for up to 6 h. The amount of con-
verted drug was determined by HPLC analysis.
PNP expression and prodrug-drug conversion after bactofec- tion with the eukaryotic expression plasmids encoding the  converting enzymes (genes were under the control of PCMV  or P4xTETP) by COS-1, 4T1 and B16 cells Figure 5
PNP expression and prodrug-drug conversion after 
bactofection with the eukaryotic expression plasmids 
encoding the converting enzymes (genes were under 
the control of PCMV or P4xTETP) by COS-1, 4T1 and 
B16 cells. (a) Western blot analysis with anti-PNP antibod-
ies performed with protein extracts of cells bactofected with 
WL-150 pSP118-PCMV-EGFP (A); WL-150 pSP118-PCMV-PNP 
(B) and WL-150 pSP118-P4xTETP-PNP (C) for 3 d or infected 
with WL-150 pSP0-PactA-SP-PNP (D) for 4 h. Equal protein 
load was confirmed by Ponceau S-staining of the nitrocellu-
lose membrane immediately after blotting. (b) Conversion of 
MePdR determined by HPLC-analysis in the supernatant of 
cell cultures 7 d after addition of 50 μM MePdR.BMC Cancer 2008, 8:94 http://www.biomedcentral.com/1471-2407/8/94
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The conversion of MePdR after infection of the mamma-
lian cells with PNP-enzyme secreting Lm reached only 25–
55% in all the cell cultures.
Discussion
In this work, we report on the construction of plasmids
encoding enzymes for prodrug-drug conversion which are
carried by a virulence-attenuated L. monocytogenes strain.
The plasmids are either equipped with eukaryotic expres-
sion cassettes encoding these enzymes or with fused genes
allowing secretion of the enzymes. In the first case the Lm
carrier strain releases the expression plasmids into the
cytosol of the cancer cells and can reach the nucleus.
There, the gene can be expressed and the active enzyme is
generated (a procedure for which the term "bactofection"
has been coined recently; [22]).
Optimal bactofection frequencies were obtained with a
stabilized balanced lethal plasmid system equipped in
addition with an autolysis cassette carried by the Lm
Δ(aroA trpS) mutant [22]. The aroA  mutation provides
good virulence attenuation [22,29] and – due to the lack
of menaquinone synthesis – leads to a predominantly
anaerobic metabolism [29]. For bactofection of the used
cancer cells we therefore applied the same plasmid system
and the aroA mutant strain which carried in addition a
deletion in aroB to further increase the biosafety of the car-
rier system [29].
The two prodrug-drug converting enzymes, the E. coli
purine-nucleoside phosphorylase (PNP) and the yeast
hybrid enzyme FCU1, used in this study can either convert
MePdR to the toxic compound MeP or Fludarabine to 2-
Fluoradenine [35]. FCU1 consists of yeast cytosine deam-
inase and uracil phosphoribosyltransferase and is also
highly active in converting 5-FC to 5-FU [27]. All three
prodrug/drug systems were functionally active in the used
cancer cell lines (COS-1, B16 and 4T1) (except Fludarab-
ine in 4T1 cells) as shown by the effective inhibition of the
Lm-infected cells after prodrug treatment compared to the
untreated cells.
When the recently described melanoma-specific P4xTETP
promoter [15] was used instead of PCMV for transcribing
the genes encoding the prodrug-drug converting enzymes
we could observe B16 melanoma specific inhibition but
survival of the non-melanoma cell lines COS-1 and 4T1.
Therefore, when targeting melanoma, security of the sys-
tem can be enhanced since gene expression will occur in
melanoma cells only.
Among the three prodrugs MePdR, Fludarabine and 5-FC,
Fludarabine appears to be least suitable as prodrug in
combination with PNP as prodrug-drug converting
enzyme. Apart from the rather low conversion rate of
Fludarabine to the toxic component by PNP, the non-con-
verted prodrug seems to be already rather cell toxic possi-
bly as a consequence of phosphorylation to the toxic
Fludarabine-ATP [36] as can be seen from the growth
inhibition in control cells. This seems to be particularly
high in 4T1 cells (Fig. 3). In vivo, the different sensitivities
to Fludarabine could pose a significant problem since
treatment of tumor cells (even when expressing the prod-
rug convering enzyme) might need Fludarabine-concen-
trations that are toxic to healthy tissues. On the other
hand, in CEM cells F-Ade is approximately 100-fold more
potent as cytotoxic agent than MeP with a Vmax/Km ratio
for the PNP-catalyzed conversion of Fludarabine to F-Ade
which is 1/1000 for that of MePdR to MeP [35].
This difference results in the inability of Fludarabine to
eradicate COS-1 and B16 cells when these cells were
infected with PNP secreting WL-150 or when B16 cells
were bactofected with the P4xTETP-deoD construct.
It is also apparent that 5-FC has some growth-inhibiting
effects on 4T1 and B16 cells (control cells in Fig. 3h and
3i), which the cells are able to overcome during the 7 days
of incubation. This could be the result of 5-FC instability
at 37°C.
Our  in vitro results show, that the Lm-mediated DNA-
delivery strategy results in a higher production efficacy of
the prodrug converting enzymes in cancer cells and a
more efficient inhibition of these cells compared to pro-
tein secretion although the fraction of cancer cells in
which PNP is expressed is higher with the latter approach.
Interestingly, Critchley et al. (2004) reported that protein
delivery is superior to DNA delivery with E. coli as carrier
(data confirming this conclusion were based on (E)GFP
delivery but no data on treatment of cancer cells with pro-
drug were provided). The higher enzyme production in
the Lm-bactofected cancer cells compared to cells infected
by Lm secreting this enzyme may hence be specific to Lm
which may not produce the same amount of protein as
does E. coli under the conditions applied. The sensitivity
of Lm to the used prodrugs, could also be an explanation
for the more efficient prodrug treatment using bactofec-
tion compared to protein delivery, however, we did not
see any growth defects when the Lm strains were coincu-
bated with the prodrugs under investigation. Even when
bacteria were grown in the presence of 50 μ M MeP (the
active drug) no growth inhibition was observed. In the
presence of 1 mM 5-Fluorouracil, we could detect growth
inhibition (data not shown), but since 5-FC is no sub-
strate for PNP, this 5-Fluorouracil mediated growth inhi-
bition can not explain the differences detected between
PNP-delivery using bactofection and protein delivery,
respectively.BMC Cancer 2008, 8:94 http://www.biomedcentral.com/1471-2407/8/94
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As we previously demonstrated several bacteria and
viruses replicate highly efficiently in tumor tissue of
tumor-bearing mice [25,37] and it was also demonstrated
that Lm is able to colonize and replicate within tumors
[26]. It can therefore be expected that the Lm-mediated
bactofection system used here for the cell culture studies
will also function in live animals. The more anoxic tumor
environment may even favour replication of the used Lm
carrier strain which exhibits a predominantly anaerobic
metabolism due to the aro mutation [29]. Even an Lm-
mediated protein-delivery approach could benefit from
the tumor specific colonization and replication of the car-
rier bacteria. Since we do not know at the moment
whether Lm-mediated delivery of expression plasmids is
also superior to protein delivery in vivo the latter approach
should also be considered for in vivo application of the
reported Lm system, especially when taking into account
that protein-delivery was advantageous compared to
DNA-delivery in vivo in terms of eliciting immune-
responses against heterologous antigens [22]. One could
also speculate that the protein delivery approach has
advantages over bactofection in vivo, because of the autol-
ysis mediated by phage lysin expression. This might
inhibit efficient bacterial spreading in tumors, thus also
reducing the observed bystander effect. Tumor-specific
promoters for the transcription of the genes encoding the
prodrug-converting enzymes may not be required as
tumor-specific expression of these enzymes may be
already guaranteed by the tumor-specific colonization of
the carrier bacteria but nevertheless, the security of the sys-
tem would be improved.
Conclusion
In summary, protein- as well as particularly DNA-delivery
by the reported virulence-attenuated Lm  carrier may
become valuable tools for future tumor therapy. A combi-
nation of both strategies may simultaneously deliver
tumor antigens and prodrug-drug converting enzymes via
the virulence-attenuated Lm carrier into a tumor-bearing
organism. This approach would thus link bacterial carrier-
supported tumor immune therapy with chemotherapy.
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